Performance vs S&P 500

03
Tracked Q1 2025–Q2 2026 +141.7%
S&P 500 total return (same window) +37.0%
Excess return +104.7%

Annualized: +102.7% · S&P 500: +28.7%

Approximates a buy-and-hold portfolio built from quarterly SEC 13F snapshots. Excludes cash, short positions, options/derivatives, and non-13(f) securities — reflects the disclosed long-equity book only, not total fund AUM. SEC filing lag is up to 45 days; this is not a real-time-copyable timing.

Priceable coverage: 98.6% · Options excluded: 0.0%

Sector breakdown

04
Healthcare 100.0%

Full portfolio 3 positions

05
Type Streak 8Q trend
SRZN Surrozen, Inc. - Common Stock $49,744,853 56.46% 1,916,950 $-6,095,901
ORIC Oric Pharmaceuticals, Inc. - Common Stock $38,346,615 43.53% 3,540,777 $-6,515,030
RVMD Revolution Medicines, Inc. - Common Stock $8,615 0.01% 46 $4,141

Top movers (QoQ)

10
SecurityActionShares ΔValue Δ
ORIC Price move only +0 -$6.5M
SRZN Price move only +0 -$6.1M
RVMD Price move only +0 +$4K

Exited positions

11

Includes corporate events (mergers, delistings) — not all exits are sells

Closed positions reflect 13F reporting changes; for index managers these are often mechanical (delisting, M&A, index rebalancing), not active decisions.

SecurityQuarterShares beforeValue beforePrice since exit
TNYA March 31, 2026 9,400,290 $6,693,006 -18.5%
RAPT March 31, 2026 156,270 $5,292,878 No longer tracked